CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
利用 IL-12 的力量：以联合策略革新肿瘤治疗
英文原题：Harnessing the Power of IL-12: Revolutionizing Cancer Therapy with Combinatorial Strategies.
查看英文原题
Harnessing the Power of IL-12: Revolutionizing Cancer Therapy with Combinatorial Strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
白细胞介素12（IL-12）是一种强效免疫刺激性细胞因子，可增强T细胞和自然杀伤（NK）细胞活化并促进Th1型免疫应答。然而，作为单药临床应用受到全身毒性和疗效有限的阻碍。因此，IL-12联合策略在癌症治疗中受到越来越多关注。本综述总结IL-12重塑肿瘤微环境并增强抗肿瘤免疫的免疫调节机制。我们讨论IL-12与免疫检查点抑制剂、化疗、CAR-T 细胞等细胞疗法及癌症疫苗联合应用的近期临床前和临床进展。此外，重点介绍靶向治疗及STING激动剂等新兴协同策略。最后，我们讨论当前挑战和未来方向，重点关注提高肿瘤特异性并减少全身毒性的策略。总体而言，本综述强调IL-12是下一代癌症联合治疗中的关键免疫调节成分。
展开英文摘要原文
Interleukin-12 (IL-12) is a potent immunostimulatory cytokine that enhances T cell and natural killer (NK) cell activation and promotes Th1-type immune responses.
However, its clinical application as monotherapy has been hampered by systemic toxicity and limited efficacy. As a result, IL-12-based combination strategies have attracted increasing attention in cancer therapy. This review summarizes the immune regulatory mechanisms by which IL-12 remodels the tumor microenvironment and enhances antitumor immunity.
We discuss recent preclinical and clinical advances in combining IL-12 with immune checkpoint inhibitors, chemotherapy, cellular therapies such as CAR-T cells, and cancer vaccines.
In addition, emerging synergistic approaches involving targeted therapies and STING agonists are highlighted.
Finally, we address current challenges and future directions, focusing on strategies to improve tumor specificity and minimize systemic toxicity.
Overall, this review emphasizes IL-12 as a key immunomodulatory component in next-generation combination cancer therapies.
论文信息
- 作者
- Zhang Y、Tian J、Cheng W、Gao X、Yin J
- 第一作者单位
- Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China.China
- 通讯作者单位
- Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China. Electronic address: junyin@cpu.edu.cn.China
- 文献类型
- 综述
- 期刊
- Cytokine2026 Sep
- 原文标识
- PubMed 42335586 · DOI 10.1016/j.cyto.2026.157180